May 22, International Day of Biodiversity.
----------------------------
Chromosome BITIBAjK
----- -----------------------
Saturday, May 21, 2011
Dental Makeover Contest In Ohio
WE WOMEN FIGHTING THE "Agreal-ACLIMAFEL-AGRADIL .." DISEASES THAT WE PRODUCED THE POISON "Learn how to acquired diseases that attack humans.
Print
Learn how he acquired some diseases that attack humans.
by Sanofi Pasteur.
In nature there are factors that make our health is compromised, it is influenced by climate change, the area where we are, at random, and even by our lack of hygiene .... -----------------------------------
AND
CONCEALMENT OF SCIENTIFIC RESEARCH, ON THE HUMAN USE DRUGS AS THEY DID WITH:
veralipride-veralipride.
Learn how he acquired some diseases that attack humans.
by Sanofi Pasteur.
In nature there are factors that make our health is compromised, it is influenced by climate change, the area where we are, at random, and even by our lack of hygiene .... -----------------------------------
AND
CONCEALMENT OF SCIENTIFIC RESEARCH, ON THE HUMAN USE DRUGS AS THEY DID WITH:
veralipride-veralipride.
Prywatne Serwery Tibi 7.6
maximum penalty for counterfeit drugs - LIMA
Print
maximum penalty for counterfeit drugs.
a pharmacist and two more machines used to produce handicrafts and other medicines bamba blisters • Ugarte Ubilluz congratulated Police work and announced that it will continue the process until you know the sentence
Health Minister Oscar Ugarte Ubilluz demanded the maximum penalty 15 years of prison sentence, which establishes the Penal Code against three people, including a pharmacist, arrested yesterday by the National Police in Chorrillos and San Martín de Porres, for machines to produce fake drugs and to craft at risk the health and lives of the population.
"This is the first capture made after the enactment of the amending some of its articles now typify these crimes, which constitute an attack against life and health our population, " revealed after congratulating the staff of the Division of Criminal Investigation and other frauds of the National Police capture.
Those arrested were identified as a pharmacist Rómulo Elías Chirito Jara (69), San Martín de Porres, the brothers José Antonio (42) and Joseph Lizardo Velarde Munoz (44) in Chorrillos, who are accused by the prosecution for alleged offenses against public health and against property - fraud.
"In this case is the maximum penalty provided for in Penal Code, which is 15 years imprisonment, as there is an aggravating factor, because the primary responsibility for the development of these drugs Counterfeit is a chemical pharmacist by profession, knows the dangers to set out the health and lives of those who use counterfeit drugs, "he said.
Article 294 in its point 'C' states that the commission of these crimes will be punished aggravated sentences of eight to fifteen years of imprisonment.
Monitor processes
Ubilluz Ugarte also expressed their commitment to remain vigilant in the process will be followed by the defendants, so that his crime does not go unpunished and said it will continue to support the work of the police against organizations involved in illegal drug trade.
"I want to publicly express my appreciation to the work done by the police because it is the first capture under the new legal framework, which is why we remain vigilant and continue to monitor investigation and judicial process to be opened only after obtaining the conviction to be issued by the judge, "said .
http://www.pysnnoticias.com/2011/05/20/pena-maxima-para-falsificadores-de-medicamentos/
maximum penalty for counterfeit drugs.
a pharmacist and two more machines used to produce handicrafts and other medicines bamba blisters • Ugarte Ubilluz congratulated Police work and announced that it will continue the process until you know the sentence
Health Minister Oscar Ugarte Ubilluz demanded the maximum penalty 15 years of prison sentence, which establishes the Penal Code against three people, including a pharmacist, arrested yesterday by the National Police in Chorrillos and San Martín de Porres, for machines to produce fake drugs and to craft at risk the health and lives of the population.
"This is the first capture made after the enactment of the amending some of its articles now typify these crimes, which constitute an attack against life and health our population, " revealed after congratulating the staff of the Division of Criminal Investigation and other frauds of the National Police capture.
Those arrested were identified as a pharmacist Rómulo Elías Chirito Jara (69), San Martín de Porres, the brothers José Antonio (42) and Joseph Lizardo Velarde Munoz (44) in Chorrillos, who are accused by the prosecution for alleged offenses against public health and against property - fraud.
"In this case is the maximum penalty provided for in Penal Code, which is 15 years imprisonment, as there is an aggravating factor, because the primary responsibility for the development of these drugs Counterfeit is a chemical pharmacist by profession, knows the dangers to set out the health and lives of those who use counterfeit drugs, "he said.
Article 294 in its point 'C' states that the commission of these crimes will be punished aggravated sentences of eight to fifteen years of imprisonment.
Monitor processes
Ubilluz Ugarte also expressed their commitment to remain vigilant in the process will be followed by the defendants, so that his crime does not go unpunished and said it will continue to support the work of the police against organizations involved in illegal drug trade.
"I want to publicly express my appreciation to the work done by the police because it is the first capture under the new legal framework, which is why we remain vigilant and continue to monitor investigation and judicial process to be opened only after obtaining the conviction to be issued by the judge, "said .
http://www.pysnnoticias.com/2011/05/20/pena-maxima-para-falsificadores-de-medicamentos/
Lip Hurts From Chewing Tobacco
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing
Print
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing.
Publication Date: May 20, 2011
Category: DRUGS FOR HUMAN USE, SAFETY.
Reference: MUH (FV) 06/2011
• The English Agency for Medicines and Health Products announced the suspension of marketing of buflomedil (Lofton ®) from 15 July 2011.
• No new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medication.
• No need to interrupt patients treatment until they come to consult your doctor.
The English Agency for Medicines and Medical Devices (Competent Authority) informed healthcare professionals about the suspension of marketing next buflomedil (Lofton ®).
Buflomedil is a peripheral vasodilator, approved in Spain in 1980 in the form of tablets and oral solution droplets. Its licensed indication is the symptomatic treatment of intermittent claudication in peripheral arterial occlusive disease stage II (see data sheet Lofton ®).
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) comprising representatives of all European national agencies, has recommended the suspension of marketing in Europe buflomedil medicines containing as active ingredient. This recommendation has been adopted after the reassessment of the benefit-risk (arbitration).
The arbitration proceedings began after the February 2011 suspension marketed in France. This suspension was due to the occurrence of serious adverse neurological and cardiac, in some cases fatal. These adverse reactions were related to accidental or intentional overdose of medication, even after the country adopted measures to reduce the risk of overdose with the drug.
For this review, the CHMP considered all available data on the benefits and risks of buflomedil, including the assessment carried out in France, data clinical trials, notifications of suspected adverse reactions and information from the literature.
The CHMP has concluded that the measures in France have not prevented the occurrence of overdoses and buflomedil has limited benefit for patients in terms of improving walking distance. Therefore, considered that expected benefits may not outweigh the potential risks.
The Commission shall publish the relevant decision to the conditions of the suspension of marketing.
Regarding the situation in Spain, the Competent Authority reports the following:
• marketing suspension Lofton ® tablets and oral solution drops Spain will become effective on 15 July, the date from which you can not prescribe or dispense the drug.
• To date, no new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medicine, taking into account the current recommendations for treating this disease is based primarily on smoking cessation, exercise and establishment of adequate antiplatelet therapy.
• It is imperative that patients discontinue the treatment until you come to the consulting your doctor.
Available the press release and document questions and answers on its website EMA (www.ema.europa.eu).
Finally recalls the importance of reporting all suspected adverse reactions to the Centre for Pharmacovigilance Autonomy.
Date updated: May 20, 2011
AEMPS Briefing Note on buflomedil (Lofton ®): suspension of marketing.
Publication Date: May 20, 2011
Category: DRUGS FOR HUMAN USE, SAFETY.
Reference: MUH (FV) 06/2011
• The English Agency for Medicines and Health Products announced the suspension of marketing of buflomedil (Lofton ®) from 15 July 2011.
• No new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medication.
• No need to interrupt patients treatment until they come to consult your doctor.
The English Agency for Medicines and Medical Devices (Competent Authority) informed healthcare professionals about the suspension of marketing next buflomedil (Lofton ®).
Buflomedil is a peripheral vasodilator, approved in Spain in 1980 in the form of tablets and oral solution droplets. Its licensed indication is the symptomatic treatment of intermittent claudication in peripheral arterial occlusive disease stage II (see data sheet Lofton ®).
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) comprising representatives of all European national agencies, has recommended the suspension of marketing in Europe buflomedil medicines containing as active ingredient. This recommendation has been adopted after the reassessment of the benefit-risk (arbitration).
The arbitration proceedings began after the February 2011 suspension marketed in France. This suspension was due to the occurrence of serious adverse neurological and cardiac, in some cases fatal. These adverse reactions were related to accidental or intentional overdose of medication, even after the country adopted measures to reduce the risk of overdose with the drug.
For this review, the CHMP considered all available data on the benefits and risks of buflomedil, including the assessment carried out in France, data clinical trials, notifications of suspected adverse reactions and information from the literature.
The CHMP has concluded that the measures in France have not prevented the occurrence of overdoses and buflomedil has limited benefit for patients in terms of improving walking distance. Therefore, considered that expected benefits may not outweigh the potential risks.
The Commission shall publish the relevant decision to the conditions of the suspension of marketing.
Regarding the situation in Spain, the Competent Authority reports the following:
• marketing suspension Lofton ® tablets and oral solution drops Spain will become effective on 15 July, the date from which you can not prescribe or dispense the drug.
• To date, no new treatments should be initiated Lofton ® and proceed to review the treatment of patients currently using this medicine, taking into account the current recommendations for treating this disease is based primarily on smoking cessation, exercise and establishment of adequate antiplatelet therapy.
• It is imperative that patients discontinue the treatment until you come to the consulting your doctor.
Available the press release and document questions and answers on its website EMA (www.ema.europa.eu).
Finally recalls the importance of reporting all suspected adverse reactions to the Centre for Pharmacovigilance Autonomy.
Date updated: May 20, 2011
Subscribe to:
Posts (Atom)